Skip to main content
. Author manuscript; available in PMC: 2014 Mar 20.
Published in final edited form as: Sci Signal. 2013 Mar 5;6(265):ra14. doi: 10.1126/scisignal.2003398

Fig. 2.

Fig. 2

WNT5A activates ARF6 through FZD4 and LRP6. (A) ARF6-GTP amounts in LOX melanoma cells treated with control (Ctrl) or WNT5A siRNAs and rescue of ARF6-GTP amounts with WNT5A conditioned medium (CM). (B) ARF6-GTP in A2058, Yusac-2, or LOX melanoma cells treated with Mock or recombinant WNT5A (rWNT5A). (C) ARF6-GTP amounts in A375, A2058, or Yusac-2 cells treated with Ctrl or WNT5A #1 or #2 siRNAs. (D) ARF6-GTP amounts in LOX cells treated with Ctrl or FZD4 siRNAs. Lower panel, reverse transcription polymerase chain reaction (RT-PCR) for FZD4 mRNA. (E) ARF6-GTP amounts in LOX cells treated with Ctrl, FZD2, FZD5, or FZD7 siRNAs. Lower panels, RT-PCR for FZD mRNAs. (F) ARF6-GTP amounts in LOX cells treated with Ctrl or LRP6 siRNAs. (G) ARF6-GTP amounts in LOX cells treated with Mock or DKK-1. For all, n = 3 independent experiments. See fig. S2 (I to O) for quantification of blots. See related experiments in figs. S9 and S10.